Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis

BACKGROUND: The monoclonal antibody (mAb) trastuzumab is part of the standard of care for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer. Antibody-dependent cell-mediated phagocytosis (ADCP) and cytotoxicity (ADCC) are major mechanisms of action of the mAb...

Descripción completa

Detalles Bibliográficos
Autores principales: Laengle, Johannes, Kabiljo, Julijan, Hunter, Leah, Homola, Jakob, Prodinger, Sophie, Egger, Gerda, Bergmann, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057438/
https://www.ncbi.nlm.nih.gov/pubmed/31940587
http://dx.doi.org/10.1136/jitc-2019-000195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057438/
https://www.ncbi.nlm.nih.gov/pubmed/31940587
http://dx.doi.org/10.1136/jitc-2019-000195

Ejemplares similares